Bergenbio First Quarter Results 2024: Advancing To The Next Stage Of Development
BERGEN, Norway, May 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL
Stay updated with breaking news from Martin Olin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BERGEN, Norway, May 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet...
BERGEN, Norway, May 28, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical
On a night at the Opera, the performance is of course the main focus. However, the interval can also serve up artistry of the highest order. The foyer
BERGEN, Norway, Nov. 14, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage...